Ozempic Just Went Generic in India: What the Semaglutide Patent Expiry Means for Pharma Investors

Saturday, Apr 11, 2026

The drug that took over the internet just became available to every Indian pharmaceutical company.

Semaglutide, the active molecule behind Novo Nordisk's Ozempic, has gone off-patent in India. For the first time, Indian generic manufacturers can produce, market, and sell their own versions of the drug freely. Several already have. And the race to capture what could be one of the most commercially significant drug categories in recent Indian pharma history has officially begun.

This is not just a healthcare story. It is an investment story. And for anyone with exposure to Indian pharma, understanding what has happened, who is positioned, and what comes next matters considerably.

What Is Semaglutide and Why Has It Become a Cultural Phenomenon?

Semaglutide belongs to a class of drugs called GLP-1 receptor agonists. It works by mimicking a hormone that regulates blood sugar and appetite, making it effective both for managing Type 2 diabetes and for weight loss. Novo Nordisk launched it as Ozempic for diabetes and later as Wegovy specifically for obesity.

What followed was unlike anything the pharmaceutical industry had seen before. The drug did not spread through clinical endorsements or hospital procurement alone. It spread through Instagram. Through celebrity interviews. Through conversations at gyms, at weddings, at workplaces. Influencers documented their weight loss journeys on it. Actors credited it publicly. A new shorthand entered everyday conversation: "Are you on Ozempic?"

The euphoria was, and continues to be, extraordinary. Demand built itself without traditional pharma marketing. Patients in India were not waiting for their doctor to suggest it. They were walking into clinics asking for it by name. Waitlists formed. Prices held stubbornly high because supply could not keep pace with a demand curve that nobody had anticipated at this scale.

This is the context in which the patent expiry has arrived. Not a routine generic entry into a clinical niche. A generic entry into a molecule with mass consumer awareness, proven clinical outcomes, and an addressable market that spans two of India's largest disease burdens simultaneously.

The Scale of the Opportunity

India's numbers make the opportunity particularly compelling.

The country has over 100 million people living with Type 2 diabetes, making it the diabetes capital of the world. Obesity, long under-reported due to stigma and inadequate clinical infrastructure, is now estimated to affect over 250 million Indians. Both conditions are growing in prevalence, driven by urbanisation, sedentary lifestyles, and dietary shifts. Both are chronically undermanaged due to access and affordability gaps.

Semaglutide addresses both in a single molecule. And with the patent gone, the price barrier that kept it out of reach for the majority of Indian patients is now falling fast. Ten Indian companies have already launched their own versions at a significant discount to Novo Nordisk's pricing. More are expected to follow.

Nomura estimates the Indian semaglutide market will reach Rs. 12,000 crore within five years, growing at a CAGR of over 30% between FY26 and FY30. That projection is not built on speculation. It is built on an existing patient base, proven demand, falling prices, and the distribution reach of India's generic pharma machinery, which is among the most capable in the world.

Why This Is a Different Kind of Generic Launch

Generic drug launches are routine in India. A patent expires, several manufacturers file, prices drop, the market expands. It happens across dozens of molecules every year.

Semaglutide is different in two important ways.

The first is the demand pull described above. Most generics require years of doctor education and institutional adoption before they gain meaningful traction. Semaglutide already has brand awareness at the consumer level that most OTC products spend decades trying to build. The moment affordability arrives, adoption accelerates far faster than a typical generic launch curve.

The second difference is the delivery format opportunity. Ozempic is an injectable. For a drug targeting obesity in a broad consumer population, injections are a meaningful adoption barrier. Several Indian manufacturers are already investing in next-generation delivery, particularly oral formulations. Whoever cracks affordable oral semaglutide at scale will have a significant and durable commercial advantage. The race for delivery innovation is as important as the race to launch.

Both of these dynamics favour companies that moved early, with genuine R&D investment and smart commercial strategy, over those that simply filed a generic and waited.

What This Means for Pharma Investors

The semaglutide patent expiry is not a one-quarter event. It is the beginning of a commercial cycle that will play out over the next five to seven years, with multiple inflection points: oral formulation launches, international market entries, biosimilar adjacencies, and ongoing price compression driving volume growth.

The companies that will capture disproportionate value from this cycle are not the ones that simply launched a product. They are the ones that built a strategy. Product innovation, distribution intelligence, and global filing readiness are the differentiators.

The Two Companies Leading the Race

Among the ten Indian companies that have launched semaglutide, two stand apart for the depth of their preparation and the intelligence of their commercial positioning.

The first is a large-cap pharma company with a significant existing presence in anti-diabetic therapy, where this category already contributes close to 10% of annual revenues. Rather than simply launching a generic, they engineered a delivery format specifically for the Indian market: a reusable, adjustable dose-pen with replaceable cartridges that makes long-term treatment meaningfully more affordable for patients than single-use injection alternatives.

More interesting is what they did on distribution. Instead of building commercial reach from scratch, they signed co-marketing agreements with two other major Indian pharma players, who will sell this company's semaglutide under their own brands in exchange for a royalty. The result is revenue flowing in from three sales channels simultaneously, without tripling the cost base. This is a company compounding an existing strength, not making a new bet.

The second is a company that moved earlier than most. Development began in 2024, and they became the first Indian company to commercially launch semaglutide, in February 2026. Their current domestic focus is diabetes injections, but the pipeline tells the more important story. An oral formulation for both diabetes and obesity is in development for 2027, which matters because oral delivery is where the true mass market lies. Injectable drugs, even affordable ones, have natural adoption limits. Whoever gets affordable oral semaglutide to Indian patients at scale will hold a durable commercial advantage.

Additionally, this company has already filed for semaglutide in 45 countries where the patent expires in 2027, turning what looks like a domestic generic play into a coordinated global launch strategy. The groundwork is done. When those markets open, they are ready to enter immediately.

Both companies were identified and held in Pharma Select before semaglutide became a mainstream investment conversation. That is the nature of the research process behind this portfolio.

The Bigger Picture

Indian pharma's structural strengths, cost competitiveness, regulatory credibility, and manufacturing scale, make it uniquely positioned to lead this cycle globally, not just domestically. The semaglutide story is a concentrated expression of a much larger thesis about what Indian pharma can do when global demand and domestic capability intersect at the right moment.

For investors looking for pharma exposure that is grounded in exactly this kind of research-led, forward-looking stock selection, Pharma Select Tracker is built around this thinking.

Explore the portfolio: Pharma Select Tracker